Figures & data
Table I. Baseline characteristics for insulin users with at least one dispensed prescription between 1 July and 31 December 2005 (cohort I), between 1 July and 31 December 2006 (cohort II), and per six-month period between 1 July 2005 and 31 December 2006 (cohort III).
Figure 2. Incidence rate ratios (IRR) of breast cancer among users of insulin glargine only compared with users of other insulins and not insulin glargine. Yearly IRRs for the follow-up period 2006–2008. Users of insulin with at least one dispensed prescription between 1 July and 31 December 2005 (cohort I).
![Figure 2. Incidence rate ratios (IRR) of breast cancer among users of insulin glargine only compared with users of other insulins and not insulin glargine. Yearly IRRs for the follow-up period 2006–2008. Users of insulin with at least one dispensed prescription between 1 July and 31 December 2005 (cohort I).](/cms/asset/19c94135-1614-47dd-9d65-2e470daf08e4/ionc_a_558913_f0002_b.gif)
Table II. Incidence rate ratio of cancer among users of insulin glargine alone compared with users of other types of insulins and not insulin glargine. Adjusted for age and sex.
Table III. Incidence rate ratio of breast cancer among women using insulin glargine only, or insulin glargine and other insulins compared with women using other insulins and not insulin glargine. Insulin use 1 July to 31 December 2005, follow-up 2006–2008.